1,272 results on '"Arbustini, Eloisa"'
Search Results
202. Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure
- Author
-
Pasotti, Michele, Agozzino, Manuela, Concardi, Monica, Merlini, Giampaolo, Rapezzi, Claudio, and Arbustini, Eloisa
- Published
- 2006
203. EARLY DIAGNOSIS OF WILSON DISEASE IN A SIX-YEAR-OLD CHILD
- Author
-
Lo Curto, Alessandro G., Marchi, Antonietta, Grasso, Maurizia, Arbustini, Eloisa, Loudianos, Georgios, and Brega, Agnese
- Published
- 2006
204. When and why do heart transplant recipients die? A 7 year experience of 1068 cardiac transplants
- Author
-
Gallo, Pietro, Baroldi, Giorgio, Thiene, Gaetano, Agozzino, Lucio, Arbustini, Eloisa, Bartoloni, Giovanni, Bonacina, Edgardo, Bosman, Cesare, Catani, Gualtiero, Cocco, Patrizia, di Gioia, Cira, Motta, Teresio, Pucci, Angela, and Rocco, Maurizio
- Published
- 1993
- Full Text
- View/download PDF
205. Enormous bi-atrial enlargement in a persistent idiopathic atrial standstill
- Author
-
Disertori, Marcello, Marini, Massimiliano, Cristoforetti, Alessandro, Dallafior, Danilo, Nollo, Giandomenico, Centonze, Maurizio, Ravelli, Flavia, Zeni, Prisca, Del Greco, Maurizio, Gramegna, Lorena, Pasotti, Michele, and Arbustini, Eloisa
- Published
- 2005
206. Identification of Sixty-two Novel and Twelve Known FBN1 Mutations in Eighty-one Unrelated Probands With Marfan Syndrome and Other Fibrillinopathies
- Author
-
Arbustini, Eloisa, Grasso, Maurizia, Ansaldi, Silvia, Malattia, Clara, Pilotto, Andrea, Porcu, Emanuele, Disabella, Eliana, Marziliano, Nicola, Pisani, Angela, Lanzarini, Luca, Mannarino, Savina, Larizza, Daniela, Mosconi, Mario, Antoniazzi, Elena, Zoia, Cristina M., Meloni, Giulia, Magrassi, Lorenzo, Brega, Agnese, Bedeschi, Maria Francesca, Torrente, Isabella, Mari, Francesca, and Tavazzi, Luigi
- Published
- 2005
- Full Text
- View/download PDF
207. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander?
- Author
-
Repetto, Alessandra, Bello, Barbara Dal, Pasotti, Michele, Agozzino, Manuela, Viganò, Mario, Klersy, Catherine, Tavazzi, Luigi, and Arbustini, Eloisa
- Published
- 2005
208. Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology
- Author
-
Pelliccia, Antonio, Fagard, Robert, Bjørnstad, Hans Halvor, Anastassakis, Aris, Arbustini, Eloisa, Assanelli, Deodato, Biffi, Alessandro, Borjesson, Mats, Carrè, François, Corrado, Domenico, Delise, Pietro, Dorwarth, Uwe, Hirth, Asle, Heidbuchel, Hein, Hoffmann, Ellen, Mellwig, Klaus P., Panhuyzen-Goedkoop, Nicole, Pisani, Angela, Solberg, Erik E., van-Buuren, Frank, Vanhees, Luc, Blomstrom-Lundqvist, Carina, Deligiannis, Asterios, Dugmore, Dorian, Glikson, Michael, Hoff, Per Ivar, Hoffmann, Andreas, Hoffmann, Erik, Horstkotte, Dieter, Nordrehaug, Jan Erik, Oudhof, Jan, McKenna, William J., Penco, Maria, Priori, Silvia, Reybrouck, Tony, Senden, Jeff, Spataro, Antonio, and Thiene, Gaetano
- Published
- 2005
209. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol: Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology
- Author
-
Corrado, Domenico, Pelliccia, Antonio, Bjørnstad, Hans Halvor, Vanhees, Luc, Biffi, Alessandro, Borjesson, Mats, Panhuyzen-Goedkoop, Nicole, Deligiannis, Asterios, Solberg, Erik, Dugmore, Dorian, Mellwig, Klaus P., Assanelli, Deodato, Delise, Pietro, van-Buuren, Frank, Anastasakis, Aris, Heidbuchel, Hein, Hoffmann, Ellen, Fagard, Robert, Priori, Silvia G., Basso, Cristina, Arbustini, Eloisa, Blomstrom-Lundqvist, Carina, McKenna, William J., and Thiene, Gaetano
- Published
- 2005
210. Release and Cleavage of Stem Cell Factor by Human Mast Cells
- Author
-
Depaulis, Amato, primary, Minopoli, Giuseppina, additional, Arbustini, Eloisa, additional, Piaz, Fabrizio Dal, additional, Pucci, Piero, additional, Russo, Tommaso, additional, Marone, Gianni, additional, and de Crescenzo, Gennaro, additional
- Published
- 2000
- Full Text
- View/download PDF
211. Human Heart Mast Cells: Immunological Characterization In Situ and In Vitro
- Author
-
Gianni, Marone, primary, De Crescenzo, Gennaro, additional, Patella, Vincenzo, additional, Granata, Francescopaolo, additional, Genovese, Arturo, additional, Verga, Laura, additional, and Arbustini, Eloisa, additional
- Published
- 2000
- Full Text
- View/download PDF
212. Genetic predisposition to heart failure
- Author
-
Pasotti, Michele, Repetto, Alessandra, Tavazzi, Luigi, and Arbustini, Eloisa
- Published
- 2004
- Full Text
- View/download PDF
213. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families
- Author
-
Obici, Laura, Palladini, Giovanni, Giorgetti, Sofia, Bellotti, Vittorio, Gregorini, Gina, Arbustini, Eloisa, Verga, Laura, Marciano, Sabrina, Donadei, Simona, Perfetti, Vittorio, Calabresi, Laura, Bergonzi, Cesare, Scolari, Francesco, and Merlini, Giampaolo
- Published
- 2004
- Full Text
- View/download PDF
214. Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients
- Author
-
Arbustini, Eloisa, Merlini, Giampaolo, Gavazzi, Antonello, Grasso, Maurizia, Diegoli, Marta, Fasani, Roberta, Bellotti, Vittorio, Marinone, Gabriella, Morbini, Patrizia, Dal Bello, Barbara, Campana, Carlo, and Ferrans, Victor J.
- Subjects
Amyloidosis -- Physiological aspects ,Health - Published
- 1995
215. Helicobacter pylori and chronic immune activation
- Author
-
Arbustini, Eloisa and Morbini, Patrizia
- Published
- 2000
216. Systemic cause of unstable atherosclerotic plaques
- Author
-
Cortellaro, Michele, Cofrancesco, Elisabetta, Arbustini, Eloisa, Gabrielli, Livio, and Tremoli, Elena
- Published
- 2000
217. Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor
- Author
-
Rampino, Teresa, Arbustini, Eloisa, Gregorini, Marilena, Guallini, Paola, Libetta, Carmelo, Maggio, Milena, Ranghino, Andrea, Silini, Enrico, Soccio, Grazia, and Dal Canton, Antonio
- Published
- 1999
218. Takotsubo Syndrome After Cesarean Section: Rare But Possible
- Author
-
Citro, Rodolfo, Lyon, Alexander, Arbustini, Eloisa, Bossone, Eduardo, Piscione, Federico, Templin, Christian, Narula, Jagat, University of Zurich, and Citro, Rodolfo
- Subjects
10209 Clinic for Cardiology ,610 Medicine & health ,2705 Cardiology and Cardiovascular Medicine - Published
- 2018
219. Thoracoscopic Treatment of Pneumothorax in Marfan Syndrome: Hemostatic Patch to Support Lung Resection Recovery
- Author
-
Pelizzo, Gloria, Arbustini, Eloisa, Pasqua, Noemi, Morbini, Patrizia, and Calcaterra, Valeria
- Subjects
Article Subject ,respiratory tract diseases - Abstract
Introduction. In selected patients, the absorbable fibrin patch TachoSil® is superior to standard surgical treatment in reducing air leakage after pulmonary lobectomy. Pulmonary involvement is not considered a main feature of Marfan syndrome (MFS); however, spontaneous pneumothorax (SP) with a high rate of recurrence is frequently reported. We describe the use of TachoSil® in the supportive treatment of recurrent pneumothorax in a girl with MFS. Case Report. A 12-year-old girl with a previous diagnosis of MFS and recurrent history of left spontaneous pneumothorax was submitted to thoracoscopic atypical lung resection. Two patches (9.5 × 4.8 cm) were cut from the adhesive/foam complex (TachoSil®) and were pressed against the sutured area as supportive treatment. The patient recovered with no further SP recurrences. Conclusions. The use of the TachoSil® surgical patch may be useful in pneumothorax supportive treatment, particularly in pediatric MFS by ameliorating the mechanical strength of the lung.
- Published
- 2018
- Full Text
- View/download PDF
220. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study
- Author
-
Prati, Francesco, primary, Romagnoli, Enrico, additional, Gatto, Laura, additional, La Manna, Alessio, additional, Burzotta, Francesco, additional, Ozaki, Yukio, additional, Marco, Valeria, additional, Boi, Alberto, additional, Fineschi, Massimo, additional, Fabbiocchi, Franco, additional, Taglieri, Nevio, additional, Niccoli, Giampaolo, additional, Trani, Carlo, additional, Versaci, Francesco, additional, Calligaris, Giuseppe, additional, Ruscica, Gianni, additional, Di Giorgio, Alessandro, additional, Vergallo, Rocco, additional, Albertucci, Mario, additional, Biondi-Zoccai, Giuseppe, additional, Tamburino, Corrado, additional, Crea, Filippo, additional, Alfonso, Fernando, additional, and Arbustini, Eloisa, additional
- Published
- 2019
- Full Text
- View/download PDF
221. Correlating Pathology to Imaging
- Author
-
Arbustini, Eloisa, primary, Urtis, Mario, additional, Prati, Francesco, additional, and Chandrashekhar, Y., additional
- Published
- 2019
- Full Text
- View/download PDF
222. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy
- Author
-
Bégué, Céline, primary, Mörner, Stellan, additional, Brito, Dulce, additional, Hengstenberg, Christian, additional, Cleland, John G F, additional, Arbustini, Eloisa, additional, Galve, Enrique, additional, Wichter, Thomas, additional, Richter, Anette, additional, Golmard, Jean-Louis, additional, Bernard, Maguy, additional, Dubourg, Olivier, additional, Komajda, Michel, additional, Charron, Philippe, additional, and Isnard, Richard, additional
- Published
- 2019
- Full Text
- View/download PDF
223. Assessment of Mechanisms of Acute Coronary Syndromes and Composition of Culprit Plaques in Patients With and Without Diabetes
- Author
-
Ruscica, Giovanni, primary, Gatto, Laura, additional, Romagnoli, Enrico, additional, Di Vito, Luca, additional, Fabbiocchi, Franco, additional, Marco, Valeria, additional, Versaci, Francesco, additional, Di Giorgio, Alessandro, additional, Taglieri, Nevio, additional, La Manna, Alessio, additional, Fineschi, Massimo, additional, Boi, Alberto, additional, Niccoli, Gianpaolo, additional, Albertucci, Mario, additional, Crea, Filippo, additional, Arbustini, Eloisa, additional, Alfonso, Fernando, additional, and Prati, Francesco, additional
- Published
- 2019
- Full Text
- View/download PDF
224. OCT/atherectomy/pathology studies open new perspectives for in vivo characterization of plaque composition
- Author
-
Arbustini, Eloisa, primary, Urtis, Mario, additional, and Prati, Francesco, additional
- Published
- 2019
- Full Text
- View/download PDF
225. Heart Failure With Obstructive, Nonobstructive, and No Coronary Artery Disease
- Author
-
Shaw, Leslee J., primary, Arbustini, Eloisa, additional, and Narula, Jagat, additional
- Published
- 2019
- Full Text
- View/download PDF
226. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology
- Author
-
Seferović, Petar M., primary, Polovina, Marija, additional, Bauersachs, Johann, additional, Arad, Michael, additional, Ben Gal, Tuvia, additional, Lund, Lars H., additional, Felix, Stephan B., additional, Arbustini, Eloisa, additional, Caforio, Alida L.P., additional, Farmakis, Dimitrios, additional, Filippatos, Gerasimos S., additional, Gialafos, Elias, additional, Kanjuh, Vladimir, additional, Krljanac, Gordana, additional, Limongelli, Giuseppe, additional, Linhart, Aleš, additional, Lyon, Alexander R., additional, Maksimović, Ružica, additional, Miličić, Davor, additional, Milinković, Ivan, additional, Noutsias, Michel, additional, Oto, Ali, additional, Oto, Öztekin, additional, Pavlović, Siniša U., additional, Piepoli, Massimo F., additional, Ristić, Arsen D., additional, Rosano, Giuseppe M.C., additional, Seggewiss, Hubert, additional, Ašanin, Milika, additional, Seferović, Jelena P., additional, Ruschitzka, Frank, additional, Čelutkiene, Jelena, additional, Jaarsma, Tiny, additional, Mueller, Christian, additional, Moura, Brenda, additional, Hill, Loreena, additional, Volterrani, Maurizio, additional, Lopatin, Yuri, additional, Metra, Marco, additional, Backs, Johannes, additional, Mullens, Wilfried, additional, Chioncel, Ovidiu, additional, de Boer, Rudolf A., additional, Anker, Stefan, additional, Rapezzi, Claudio, additional, Coats, Andrew J.S., additional, and Tschöpe, Carsten, additional
- Published
- 2019
- Full Text
- View/download PDF
227. Genetics and clinics: current applications, limitations, and future developments
- Author
-
Di Toro, Alessandro, primary, Giuliani, Lorenzo, additional, Favalli, Valentina, additional, Di Giovannantonio, Matteo, additional, Smirnova, Alexandra, additional, Grasso, Maurizia, additional, and Arbustini, Eloisa, additional
- Published
- 2019
- Full Text
- View/download PDF
228. Personalised risk stratification of acute coronary syndromes calls for a less broad grouping of MACE
- Author
-
Prati, Francesco, primary, Gatto, Laura, additional, and Arbustini, Eloisa, additional
- Published
- 2019
- Full Text
- View/download PDF
229. Introductory editorial
- Author
-
Prati, Francesco, primary, Arbustini, Eloisa, additional, and Albertucci, Mario, additional
- Published
- 2019
- Full Text
- View/download PDF
230. Penetrating Atherosclerotic Ulcer of the Ascending Aorta Found Incidentally in a 71-Year-Old Man
- Author
-
Grande, Antonino M., primary, Di Perna, Dario, primary, Valentini, Adele, primary, and Arbustini, Eloisa, primary
- Published
- 2019
- Full Text
- View/download PDF
231. A new variant of Bernard-Soulier syndrome characterized by dysfunctional glycoprotein (GP) Ib and severely reduced amounts of GPIX and GPV
- Author
-
Noris, Patrizia, Arbustini, Eloisa, Spedini, Pierangelo, Belletti, Simona, and Balduini, Carlo Luigi
- Published
- 1998
232. Balance in patients with Marfan syndrome
- Author
-
Monteleone, Serena, primary, Feltroni, Lucia, additional, Arbustini, Eloisa, additional, De Bernardi, Elisabetta, additional, Carenzio, Gabriella, additional, Toffola, Elena Dalla, additional, and Schieppati, Marco, additional
- Published
- 2018
- Full Text
- View/download PDF
233. Inflammation, Superadded Inflammation, and Out-of-Proportion Inflammation in Atherosclerosis
- Author
-
Narula, Jagat, primary and Arbustini, Eloisa, additional
- Published
- 2018
- Full Text
- View/download PDF
234. In Vitro Generation of Human Cytomegalovirus pp65 Antigenemia, Viremia, and LeukoDNAemia
- Author
-
Revello, Maria Grazia, Percivalle, Elena, Arbustini, Eloisa, Pardi, Ruggero, Sozzani, Silvano, and Gerna, Giuseppe
- Published
- 1998
235. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease
- Author
-
Arbustini, Eloisa, Pilotto, Andrea, Repetto, Alessandra, Grasso, Maurizia, Negri, Andrea, Diegoli, Marta, Campana, Carlo, Scelsi, Laura, Baldini, Elisa, Gavazzi, Antonello, and Tavazzi, Luigi
- Published
- 2002
- Full Text
- View/download PDF
236. Human Synovial Mast Cells: I. Ultrastructural In Situ and In Vitro Immunologic Characterization
- Author
-
de Paulis, Amato, Marino, Isabella, Ciccarelli, Anna, de Crescenzo, Gennaro, Concardi, Monica, Verga, Laura, Arbustini, Eloisa, and Marone, Gianni
- Published
- 1996
237. Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction
- Author
-
Arbustini, Eloisa, Grasso, Maurizia, Fasani, Roberta, Klersy, Catherine, Diegoli, Marta, Porcu, Emanuele, Banchieri, Nadia, Fortina, Paolo, Danesino, Cesare, and Specchia, Giuseppe
- Published
- 1995
238. Oxalic Cardiomyopathy: Could it Influence Treatment Plans in Patients With Primary Hyperoxaluria Type 1?
- Author
-
Di Toro, Alessandro, Urtis, Mario, Giuliani, Lorenzo, Pellegrini, Carlo, Smirnova, Alexandra, Galato, Raffaele, Valentini, Adele, Jallous, Hussein, Scaccabarozzi, Sergio, and Arbustini, Eloisa
- Published
- 2021
- Full Text
- View/download PDF
239. APOPTOSIS AND THE SYSTOLIC DYSFUNCTION IN CONGESTIVE HEART FAILURE: Story of Apoptosis Interruptus and Zombie Myocytes
- Author
-
Narula, Jagat, Arbustini, Eloisa, Chandrashekhar, Y., and Schwaiger, Markus
- Published
- 2001
- Full Text
- View/download PDF
240. Expression of proliferating cell markers in normal and diseased human hearts
- Author
-
Arbustini, Eloisa, Diegoli, Marta, Grasso, Maurizia, Fasani, Roberta, D'Armini, Andrea, Martinelli, Luigi, Goggi, Claudio, Campana, Carlo, Gavazzi, Antonello, and Vigano, Mario
- Subjects
Heart muscle -- Physiological aspects ,Muscle cells -- Physiological aspects ,Heart diseases -- Physiological aspects ,Health - Abstract
Proliferating coll nuclear antigen (PCNA) myocyte expression and histoputhologic features related to its occurrence were investigated in normal and diseased hearts of adult humans using both inimunohistochemical and Western blotting techniques. Ki67 Western blotting was also performed in the same samples used for PCNA blotting. Two hundred seventy-one endomyocardial biopsies, and 15 adult, 1 embryonic and 2 fetal hearts were studied. The biopsies were from normal donor hearts (n = 71), patients with cardiomyopathy and myocarditis (n = 64), and patients with transplantation with (n = 106) and without (n = 30) acute rejection of any grade. The 1S hearts were from 1 heart donor, and from patients with cardiomyopathy (n = S), valvular heart disease (n = 2), ischemic heart disease (n = 4), amyloidosis (n = 1) and transplantation with acuto rejection (n = 2). The PCNA labeling index was plotted against myocyte hypertrophy, inflammatory infiltrates and binucleation index. The PCNA labeling index ranged from 2 to 9% in embryonic and fetal hearts. PCNA was expressed by 1 to 2% of myocyte nuclei in 12% of normal heart biopsies, 1 to 5% of myocyte nuclei in 28% of cardiomyopathy and myocarditis biopsies, and by up to 8% of myocyte nuclei in 53% of biopsies of patients with transplantation, independently of the presence and degree of acute rejection. In the latter biopsies and in myocarditis, some inflammatory cells also showed PCNA expression. PCNA positive myocytes were both mono- and binucleated, and there was no correlation between binucleation and PCNA labeling indexes. Ki67 and PCNA blotting confirmed immunohistochemical results. The results show that few myocytes express PCNA in normal hearts. This expression is only detectable by immunohistochemical stains. The percentage of PCNA expressing myocytes increases in diseased hearts of any origin, so that it becomes detectable by both immunohistochemical and Western blotting techniques. Data from transplanted heart biopsies confirm that as in myocarditis, immunologic-inflammatory stimuli are likely powerful triggers of PCNA expression. Therefore, cardiac myocytes of adult humans can express proliferating cell markers, and this expression increases in hearts with hypertrophy or inflammatory reaction. (Am J Cardiol 1993;72:608-614) Embryonic and fetal hearts grow through proliferation of differentiated cardiac myocytes. A few days after birth, myocardial tissue loses its proliferative 'capacity' and soon becomes a 'non-dividing' tissue.[1,2] Growth of myocytes in neonatal rats can be divided into 3 different phases: hyperplastic, transitional and hypertrophic. Myocyte binucleation is considered an early marker of growth hypertrophy and could be the result of mitosis without cytokinesia.[3] Therefore, deoxyribonucleic acid (DNA) of non-dividing cells is probably renewed by mechanisms other than mitotic cell division. The biological half-life of myocyte DNA is estimated to be approximately 40 days with the labeled thymidine method.[4] Given the absence of mitotic division in the myocardium of adult humans,[1-4] the only methods available for investigating possible DNA renewal are those that study cell cycle phases.[4,5] Both thymidine[4] and bromodeoxiuridine incorporation[5] require in vivo administration, but there are no indications for administration of bromodeoxyuridine in cardiac disorders to increase susceptibility of cells to lethal effects of x-radiation, as in neoplastic diseases.[6] Conversely, immunohistochemical methods that detect cell cycle-related antigens can be safely and usefully employed. Examples include Ki67, which identifies a nuclear antigen expressed in all phases except GO,[7,8] and proliferating cell nuclear antigens (PCNA), which are similarly expressed in late G1, S, G2 and M phases of cell cycles.[9,10] The former can be detected only in frozen tissue, whereas the latter can be studied in formalin-fixed, paraffin-embedded samples, because it reacts with a formalin-resistant epitope of PCNA (cyclin). A recent experimental study performed in rat cardiomyocytes demonstrated PCNA messenger ribonucleic acid but not PCNA protein expression in nondividing adult cardiac muscle cells, suggesting post-transcriptional PCNA regulation.[11] To investigate proliferating cell markers in human adult cardiac myocytes and stimuli influencing their expression, we performed immunohistochemical and Western blotting studies using PCNA and Ki67 antibodies in normal and diseased hearts, including cardiomyopathies, other heart diseases and transplanted hearts. PCNA is a 36 KDa nuclear protein that has been identified as an auxiliary molecule of DNA polymerase [sigma].[9] PCNA labeling index correlates with flow cytometric determination of S phase fraction,[12] tritiated thymidine labeling index,[9,13] bromodeoxyuridine incorporation[13,14] and Ki67 labeling index.[15] METHODS Materials: Two embryonic, 1 fetal and 15 adult hearts, and 271 endomyocardial biopsies were investigated. Seventy-one biopsies were from normal donor hearts (22 female and 49 male; mean age 34.4 [+ or -] 13.5 years, range 14 to 61). The hearts had 129 [+ or -] 49 minutes (range 37 to 260) of ischemia between explantation from donor and transplantation. Sixty-four biopsies were from patients (17 women and 47 men; mean age 45 [+ or -] 12 years, range 20 to 62) with the clinical diagnosis of dilated cardiomyyopathy (n = 58), restrictive cardiomyopathy (n = 3), myocarditis (n = 1), Loeffler disease (n = 1) and hypertrophic cardiomyopathy (n = 1). Large right ventricular samples from normal and diseased hearts were also investigated with immunohistochemical and Western blotting methods (see later) to confirm small biopsy results. Finally, 136 biopsies were from transplanted hearts (Table I). All endomyocardial biopsies were perfomed according to the Stanford technique.[16] Four to 6 adequate samples for each procedure were fixed in 10% buffered formalin (20 minutes), dehydrated in a modified alcohol series (95% alcohol: 15 minutes, and 100% alcohol: 15 minutes) and xylene (15 minutes), and embedded in a single paraffin block.[17] For normal donor and idiopathic dilated cardiomyopathy biopsies, 45 sections were serially cut and consecutively collected on 15 slides, and stained at 3 cutting levels (every 75[mu]m) with hematoxylin-eosin and Masson's trichrome or Movat pentachrome. For biopsies from patients with transplantation, 120 sections were serially cut, consecutively collected on 40 slides and similarly stained at 6 cutting levels. Unstained sections were used for immunohistochemical studies. Hispathologic evaluation of endomyocardial biopsies: Normal donor biopsies were studied using previously reported methods and criteria.[18] Idiopathic dilated cardiomyopathy biopsies were evaluated following histopathologic parameters described previously.[19] Acute cardiac rejection was diagnosed according to Stanford criteria and grading.[20] We only distinguished between focal (type A) and diffuse (type B) moderate rejection, with special reference to extension of myocyte damage and necrosis.[21] In the present study, transplantation biopsies are reported with both original diagnosis and grade, and Working Formulation--International Society of Heart Transplantation new grading for acute rejection.[22] Light microscopy immunohistochemistry: Immunohistochemical staining was performed on sections consecutive to those stained with hematoxylin-eosin, Masson's trichrome and Movat pentachrome. Sections were deparaffinized and brought to Tris-phosphate-buffered saline solution (Tris-buffered saline 0.15 M, pH 7.35). After blocking endogenous peroxidase with 3% [H.sub.2][O.sub.2], and pretreatment with type XXVII protease (Sigma Chemicals, St. Louis) or trypsin, the slides were incubated overnight with the primary antisera. Immunohistochemical staining was performed with the peroxidase-antiperoxidase method[23] and avidin-biotin complex technique.[24] Diaminobenzidine (Sigma) was used as chromogen substrate. Specificity tests, performed by omission of the first layer, produced negative results. PCNA monoclonal antibodies were commercially obtained (Dako A/S, Denmark). The optimal working dilution was 1:300. Titration tests were performed on routinely fixed specimens, including normal (lymphatic and epithelial) and neoplastic (breast carrinomas, central nervous system neoplasms and bowel tumors). Quantitation of binucleated and proliferating cell nuclear antigen-labeled nuclei: The percentages of binucleated myocytes and immunolabeled nuclei were semiquantitatively evaluated in all samples using 25 X objective lens. Binucleation was evaluated in longitudinally cut myocytes. In cases with significant field-to-field variation, the highest and lowest scores were indicated. We used this method because no image analysis system can distinguish between myocyte and endothelial or interstitial cell nuclei. In addition, semiquantitative techniques have been reported to provide reproducible and useful results in other tissues.[12] Immunoblotting: We also used immunoblotting techniques on multiple samples to test the presence and specificity of anti-PCNA antibodies. The samples were from the following heart types: 1 normal donor (24-year-old man who died from cerebral trauma); 5 with idiopathic dilated cardiomyopathy; 4 with coronary artery disease; 2 with valvular heart disease; 1 explanted heart with amyloidosis; and transplanted hearts with acute rejection obtained at either retransplantation (n = 1) or autopsy (n = 1). All but 1 of the samples were from men in the age range of 24 to 58 years (mean 47.5 [+ or -] 10.4). Biopsy samples are usually too small to extract adequate amounts of protein for blotting. Methods were previously described in detail.[25] Polyacrylamide 10% gel electrophoresis was performed according to the Laemmly method.[26] Proteins were transferred to nitrocellulose according to Towbin et al.[27] The presence of Ki67 antigen (Ki67 monoclonal antibody, Dako A/S) was also tested in the samples used for PCNA blotting and for immunohistochemical stains by sodium dodecyl sulphate polyacrylamide gel electrophoresis with a low percentage (5%) acrylamide stab gel system.[28] The membranes were then incubated with the primary antibodies for 1 hour. Bound antibody was targeted with alkaline phosphatase conjugated with goat anti-mouse immunoglobulin G. Finally, bound alkaline phosphatase was visualized following the method of Leary et al.[29] Statistical analysis: To verify the presence of association between categoric variables (Table II), chi-square tests were performed, and C contingency coefficients were computed for the normal heart donor group, as well as for the cardiomyopathy group. The variable 'age' was transformed into 20-year interval classes for testing against other variables. For testing between ordinal variables, Kendall tau coefficients were also computed. RESULTS PCNA-immunolabeled nuclei were sharp and easily identified in both myocyte and interstitial cells. Only myocyte nuclei were considered. Nuclear staining pattern were both diffuse and finely reticular, and exhibited variable intensity. Immunohistochemical results in fetal hearts: Embryonic and fetal hearts had a high PCNA labeling index ranging from 2 to 9% (Figure 1). The highest scores were obtained from the interventricular septum and left ventricular walls. Immunohistochemical results in normal donor biopsies: PCNA labeling was detected in myocyte nuclei of 8 of 71 donor biopsies (11.27%). Few positive endothelial and interstitial mesenchymal cells were observed in 1 case. In the 8 positive cases, the PCNA labeling index ranged from 1 to 2%. Binucleated myocytes were observed in 50 of 71 biopsies (70.42%), and binucleation index ranged from 0 to 3%. Myocyte hypertrophy (transversal 0 >20 [mu]m) was found in 25 biopsies (35.2%), and some fibrosis in 24 (33.8%). No relation was observed between PCNA labeling, and age, myocyte hypertrophy and binucleation (Table II), because PCNA protein expression was detected in both mono--and binucleated myocytes (Figure 2). Immunohistochemical results in biopsies of patients with idiopathic dilated cardiomyopathy: Histopathologic study of the biopsies of patients with idiopathic dilated cardiomyopathy showed features consistent with cardiomyopathy in 31 cases (including 1 arrhythmogenic right ventricular disease), myocyte hypertrophy or interstitial fibrosis, or both, in 13, granulomatous myocarditis in 3, healing myocarditis in 2, isolated myocyte hypertrophy in 7, Loeffler endocardial disease in 1, endomyocardial fibrosis in 1, small vessel disease in 1, cardiac amyloidosis in 1, sparse lymphocytes with no hypertrophy or fibrosis in 1, and histologically normal myocardial tissue in 3. PCNA labeling index showed high field-to-field variation in the percentage of positive cells, ranging from 1 to 4% in positive cases. Binucleation index varied from 0 to 5%. The intensity and pattern of immunoreactivity were similar to those observed in normal donor biopsies, but positive immunoreaction occurred mostly (but not exclusively) in hypertrophic cardiomyopathy and huge, bizarre nuclei of idiopathic dilated cardiomyopathy biopsies (Figure 3). In myocarditis and the Loeffler case, some inflammatory cells had sparse labeled nuclei that were not counted. An association was found between age and binucleation index on the one hand (Kendall tau - 0.245), and between PCNA and binucleation index with a higher contingency coefficient on the other (Table II). Immunohistochemical results in transplanted heart biopsies: In this series, we detected a very high percentage of positive biopsies (53%). Grouping of these biopsies according to presence of acute cardiac rejection and degree of rejection itself revealed no difference between rejection-free biopsies (Figure 4, a, b and c) and those with mild (Figure 4d) or moderate Figure 5, a and b) rejection (Table I). Contrary to idiopathic dilated cardiomyopathy and noninflammatory diseases, and analogous to inflammatory diseases, interstitial inflammatory cells other than myocytes showed definite nuclear immunostaining. PCNA myocyte labeling index was higher in transplanted hearts than normal or idiopathic dilated cardiomyopathy hearts, reaching values as high as 8%. Immunoblotting results: Antibodies to PCNA recognized a 36 KDa-band polypeptide in immunoblotting studies of large samples from hearts with idiopathic dilated cardiomyopathy, ischemic heart disease, valvular heart disease, amyloidosis and acute rejection, whereas no bands were observed in normal heart samples. Negative immunoblotting findings in normal heart samples indicate that the method does not detect the small amounts of PCNA protein clearly shown by immunohistochemical study. Antibodies to Ki67 recognized a 354 KDa polypeptide not only in the same samples expressing PCNA (9 of 14 diseased hearts; 62.3%), but also in 3 additional cases (12 of 14; 85.7%). Comparison between different methods: Immunohistochemical stains detected single PCNA-positive nuclei, whereas blotting did not detect the very low protein amount present in normal hearts. The probability of finding PCNA immunoreactivity increased with sample size, so that PCNA expression was found in 40% of large versus 26% of small idiopathic dilated cardiomyopathy biopsies. In addition, PCNA expression was not influenced by preservation. When using Western blotting techniques on extracts from nonfixed tissue, we found that 40% of idiopathic dilated cardiomyopathy myocardial samples expressed PCNA. Some PCNA derived from myocyte nuclei, because immunohistochemical staining did not show labeling of interstitial or endothelial cell nuclei in idiopathic dilated cardiomyopathy samples. Finally, blotting with Ki67 revealed 80% of idiopathic dilated cardiomyopathy samples to be positive (Table III). The highest Ki67 expression found by blotting in diseased hearts was probably related to its large size and high molecular weight. DISCUSSION This is the first report documenting expression of PCNA protein in normal adult human myocytes. PCNA expression increases in different disorders primarily affecting myocardium, such as idiopathic dilated cardiomyopathy and myocarditis, and in transplanted hearts where myocardial tissue is subjected to chronic immunologic stimuli. This PCNA expression suggests the possibility that periodic DNA renewal occurs in human adult myocytes, and that expression rate can be influenced by hypertrophy and immune- or inflammatory-mediated stimuli. Therefore, although myocardium is a non-dividing tissue, mechanisms other than mitotic cell replication could intervene in DNA renewal in stimulated myocytes. The data provide new insights into myocardial expression of proliferating cell markers. Functionally normal adult myocardium: There is definite evidence that during fetal life cardiac muscle cells synthesize DNA and divide.[1,2,4] Our embryonic and fetal hearts did not show mitosis, but did show PCNA immunoreactivity. This is in accordance with blotting data reported by Marino et al.[11] The percentage of labeled myocytes (labeling index) after 24 hours of ([sup.3]H)thymidine incorporation is inversely related to heart growth, so that the labeling index is at a maximum during early fetal life, progressively reduces after birth and is negligible by the end of the third week.[4] The present results in normal donor biopsies are in accordance with data obtained from experimental animals. We found PCNA-labeled myocyte nuclei in 12% of normal biopsies. In the positive cases, the PCNA labeling index was very low (1 to 2%). Other studies investigating myocardial PCNA expression did not find any staining in adult cardiac myocytes.[10] These different results could be related to technical processing of biopsy samples. Fixation time can greatly alter detection of PCNA immunoreactivity. The short fixation time, together with previously described, modified processing methods[17] used in this study, could explain these differences. We did not find any significant correlation between PCNA protein expression and age, hypertrophy and binucleation index in the normal heart group. Binucleated cardiac myocytes, early indicators of growth hypertrophy,[3] are a frequent finding in normal adult human hearts, representing up to 3% of myocytes. In the present study, PCNA immunolabeling was detected in some binucleated myocytes, whereas it was not found in many other binucleated myocytes. Therefore, binucleation and PCNA protein expression are not necessarily related to each other. The negative results obtained by blotting with PCNA in normal hearts confirms that the amount of PCNA protein is too small to be detected by this technique. The negative results obtained in normal heart samples with Ki67 blotting could have 2 possible interpretations. The first possibility is that Ki67 is not expressed at al, whereas the second is that as with PCNA, the technique is not sufficiently sensitive to detect small amounts of Ki67 possibly expressed in normal hearts. The present PCNA blotting results are in accordance with those reported by Marino et al[11] in their Western blotting study of adult experimental hearts. Conversely, immunohistochemical techniques proved to be more sensitive than did blotting, because they detected PCNA protein expression even in single cells and were also more useful for precisely defining labeled cell phenotype. Accordingly, very low but definite PCNA expression in functionally normal, adult human hearts suggests that there is a low but constant rate of DNA synthesis, indicating the possibility of amitotic DNA renewal. Diseased adult hearts: Percentages of PCNA immunolabeling in this series varied according to pathologic entities, reaching a maximal value in myocarditis and the lowest percentages in cardiomyopathies; in the former, positive myocyte nuclei were found in all biopsies, whereas in the latter, the incidence of positive cases was twice that of normal hearts. The paucity of cases with other, rarer disorders prevents consideration of such disorders. However, there is a trend toward increasing expression of PCNA from normal to diseased hearts with abnormal stimuli, such as inflammation or hypertrophy. Previous studies indicated that as diseased hearts increase in size and age, the ploidy of the cardiac muscle cells increases.[30-32] Those data suggest that some new DNA synthesis occurs in human adult cardiac myocytes, and are in accordance with our finding of PCNA positivity in cases with hypertrophy of any origin and nature (i.e., primary, such as in cardiomyopathy, or secondary, such as that of valvular heart disease). Binucleation correlated with patient age, suggesting that it can be an age-related feature (as can hypertrophy).[18] In addition, in cardiomyopathy hearts, binucleation index correlated with PCNA nuclear immunolabeling, although some positive nuclei were single. This result could be consistent with abnormal DNA renewal or repair[33] in huge nuclei often observed in cardiomyopathies.[19] With respect to normal control cases, PCNA overexpression by myocyte nuclei in the different primary or secondary noninflammatory disorders, as well as Ki67 expression found by blotting, suggests that proliferating cell antigen expression increases in hearts with stimuli of any origin and type. The actual significance of PCNA immunolabeling in myocarditis is not clear. Inflammation could stimulate myocyte DNA renewal, as well as cause cardiac damage needing DNA repair.[33] Accordingly, myocytes could respond to inflammatory stimuli by regenerating their sarcoplasmatic and sarcolemmal components after DNA renewal or repair. In any PM of myocardial inflammatory injury, nuclei are the last cell components to die. Transplanted heart biopsies: The highest percentages of PCNA protein expression, together with the highest PCNA labeling index, were found in biopsies from transplanted hearts. The presence of acute rejection of any degree (mild or moderate) did not influence PCNA expression, because positive nuclei were observed in biopsies both with and without acute rejection. The PCNA labeling index was also similar in rejection and nonrejection groups, suggesting that permanent immunologic stimuli, rather than grade, probably influence expression of DNA renewal markers. The presence of labeled nuclei in the interstitial inflammatory or mesenchymal cells was not related to myocyte nuclei labeling, because the latter was found in areas both with and without infiltrates. The positive blotting results for both PCNA and Ki67 in transplanted hearts with acute rejection could be due to both myocytes and inflammatory or interstitial positive cells detected by immunohistochemistry. However, immunohistochemical study showed that at least part of immunoreactivity is definitely due to myocyte nuclei PCNA expression. The high expression of cell proliferation markers in denervated, transplanted hearts could be positive for myocardial well-being. However, we are still far from understanding the mechanisms regulating myocardial cell replication or renewal. The very recent demonstration that PCNA is needed for DNA excision repair[33] suggests an alternative explanation for PCNA expression in normal and diseased myocardium in humans. In conclusion, the unexpected expression of cell proliferation markers such as PCNA and Ki67 in diseased human adult hearts suggests that myocardium may increase its DNA renewal or repair rate as a result of inflammatory or immunologic injuries and of stimuli triggering primary or secondary hypertrophy. Aknowledgment: We thank Emanuele Porcu for technical assistance, and Linda D'Arrigo for English revision. [1.] Peterson RO, Baserga R. Nucleic acid and protein synthesis in cardia muscle of growing and adult mice. Exp Cell Res 1965;40:340-352. [2.] Rumayantsev PP. Interrelations of the proliferation and differentiation processes during cardiac myogenesis and regeneration. Int Rev Cytol 1977;51:187-273. [3.] Clubb FJ, Bishop SP. Formation of binucleated myocardial cells in the neonatal rat. Lab Invest 1984;50:571-577. [4.] Pelc SR. Labelling of DNA and cell division in so called non-dividing tissues. J Cell Biol 1964;22:21-28. [5.] Sugihara H, Hattori T, Fukuda M. Immunohistochemical detection of bromodeoxyuridine in formalin-fixed tissues. Histochemistry 1986;85:193-195. [6.] Kriss JP, Maruyama Y, Tung LA, Bond SB, Revesz L. The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine and 5-iododeoxycytidine in man. Cancer Res 1963;23:260-268. [7.] Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715. [8.] Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489-503. [9.] Mathews MB, Bernstein RM, Franza BR Jr, Garrels JI. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984;309:374-376. [10.] Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162:285-294. [11.] Marino TA, Haldar S, Williamson EC, Beaverson K, Walter RA, Marino DR, Beatty C, Lipson KE. Proliferating cell nuclear antigen in developing and adult rat cardiac muscle cells. Circ Res 1991;69:1353-1360. [12.] Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti PCNA/cyclin monoclonal antibodies in fixed, embedded tissue. Comparison with flow cytometric analysis. Am J Pathol 1989;134:733-739. [13.] Buttersby S, Andersen TJ. Correlation of proliferative activity in breast tissue using PCNA/cyclin. Hum Pathol 1990;21:781. [14.] Coltrera MC, Gown AM. PCNA/cyclin expression and BrdU uptake define different cell subpopulation in different cell lines. J Histochem Cytochem 1991; 39:23-30. [15.] Levison DA, Hall PA, Woods AL, Yu C, Barnes DM, Wasseem N, Lane DP. Evaluation of PCNA (proliferating cell nuclear antigen) immunostaining as a marker of cell proliferation in formalin-fixed paraffin-embedded tissues (abstr). J Pathol 1990;161:341. [16.] Caves PK, Stinson EB, Billingham ME, Shumway NE. Percutaneous transvenous endomyocardial biopsy in human heart recipients. Ann Thorac Surg 1973; 16:325-336. [17.] Arbustini E, Grasso M, Diegoli M, Bramerio M, Scotti Foglieni A, Albertario M, Martinelli L, Gavazzi A, Goggi C, Campana C, Vigano M. Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical and immunoblotting study. Am J Pathol 1991;139:707-715. [18.] Arbustini E, Gavazzi A, Pozzi R, Pucci A, Grasso M, Diegoli M, Campana C, Graziano G, Martinelli L, Goggi C, Montemartini C, Vigano M. Endomyocardial biopsy of normal heart before cardiac transplantation. A morphologic and morphometric study in 97 cases. Am J Cardiovasc Pathol 1992;4:1-8. [19.] Arbustini E, Gavazzi A, Pozzi R, Grasso M, Pucci A, Campana C, Graziano G, Martinetti M, Cuccia MC, Martinelli L, Salvaneschi L, Montemartini C, Vigano M. The morphologic spectrum of dilated cardiomyopathy and its relation to immune-response genes. Am J Cardiol 1989;64:991-995. [20.] Billingham Me. Diagnosis of cardiac rejection by endomyocardial biopsy. Heart Transplant 1981;1:25-29. [21.] Arbustini E, Grasso M, Diegoli M, Gavazzi A, Campana C, Martinelli L, Goggi C, Pucci A, Grossi P, Ippoliti C, Vigano M. La biopsia endomiocardica nel paziente cardiotrapiantato: stato dell'arte. G Ital Cardiol 1991;21:1107-1123. [22.] Billingham ME, Cary NRB, Hammond ME, Kemnitz J, Marboe C, McA]lister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 1990;9:587-593. [23.] Stemberger LA. The unlabelled antibody enzyme peroxidase-antiperoxidase (PAP) method. In: Stemberger LA, ed. Immunocytochemistry. New York: John Wiley, 1979:104-169. [24.] Hsu SM, Rainel L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981;29:577-580. [25.] Arbustini E, Pucci A, Grasso M, Diegoli M, Pozzi R, Gavazzi A, Graziano G, Campana C, Goggi C, Martinelli L, Silini E, Specchia G, Vigano M, Solcia E. Expression of natriuretic peptide in ventricular myocardium of failing human hearts and its correlation with the severity of clinical and hemodynamic impairment. Am J Cardiol 1990;66:973-980. [26.] Laemmly UK. Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature 1970;227:680-685. [27.] Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4354. [28.] Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-873. [29.] Leary JJ, Brigatti DJ, Ward DC. Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized tp DNA or RNA immobilized on nitrocellulose: bioblots. Proc Natl Acad Sci U S A 1983;80:4045-4049. [30.] Anversa P, Olivetti G, Loud AV. Morphometric study of early postnatal development in the left and right ventricular myocardium of the rat. Circ Res 1980;46:495-502. [31.] Brodsky WJ, Arefyeva AM, Uryvaeva IV. Mitotic polyploidization of mouse heart myocytes during the first postnatal week. Cell Tissue Res 1980;210:133-144. [32.] Sandritter W, Scomazzoni G. Deoxyribonucleic acid content (Feulgen photometry) and dry weight (interference microscopy) of normnal and hypertrophic heart muscle fibres. Nature 1984;202:100-101. [33.] Shivij MKK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992;69:367-374. From the Pathology, Cardiac Surgery, and Cardiology Departments, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS, Policlinico San Matteo, Universita di Pavia, Pavia, Italy. This study was supported by grants 'Trapianto Cardiaco' and 'Trapianto Cuore-Polmoni' from Health Ministry to IRCCS, Policlinico San Matteo, Pavia-Ricerche Finalizzate 1989-1990. Manuscript received October 23, 1992; revised manuscript received March 8, 1993, and accepted March 19. Address for reprints: Eloisa Arbustini, MD, Dipartimento di Patologia Umana ed Ereditaria, Sezione di Anatomia Patologica, Via Forlanini 14, 27100 Pavia, Italy.
- Published
- 1993
241. Morphologic changes induced by acetylcholine infusion in normal and atherosclerotic coronary arteries
- Author
-
Arbustini, Eloisa, Grasso, Maruizia, Diegoli, Marta, Bellini, Ornella, Ghio, Stefano, DeServi, Stefano, Martinelli, Luigi, Vigano', Mario, and Specchia, Giuseppe
- Subjects
Acetylcholine -- Physiological aspects ,Coronary arteries -- Dilatation ,Atherosclerosis -- Physiological aspects ,Health - Abstract
Low doses of acetylcholine induce 'endothellum-dependent' dilatation in normal coronary arteries and constriction of diseased vessels. This study investigated morpholoigic changes induced by perfusion of normal and diseased coronary arteries with low and high doses of acutylchollne. Vessels were excised from a series of beating hearts explanted at transplantation for idiopathic dilated cardliomyopathy and coronary artery dim. Coronary arteries from other explanted hearts, perfused with saline solution under similar conditions were taken as control. Samples were studied using conventional histopathologic and immuno-histochemical methods. Coronary arteries were grouped according to presence or absence of his tologically detectable structural modifications of any type and extent. Low doses of acetylcholine Induced changes In all but 1 structurally diseased coronary artery, whereas no change was induced in any but 1 histologically normal coronary artery. High doses of acetylcholine induced contraction changes In both normal diseased vessels. Changes observed in the wall of the contracted vessels were: (1) endothelial cell contraction with protruding nuclei and detachment of their intercellular junctions with exposure of subject collaget to flow, (2) contraction of plaque smooth muscle cells, (3) formation of cushions protruding Into vessel lumens causing blunt microchannels. Contraction in both intimal and plaque culls occurred even in diseased vessel segments with intimal denudation. These effects seemed to be dose-dependent in structurally normal vessels because low doses of acetyicholine did not produce any morphologically detectable changes in histologically normal coronary arteries, while low domes of acetyicholine induced similar reactions in vessels affected by both atherosclerosis and subintimal flbrocellular thickening. (Am J Cardiol 1993;71:1382-1390)
- Published
- 1993
242. Search for coxsackievirus B3 RNA in idiopathic dilated cardiomyopathy using gene amplification by polymerase chain reaction
- Author
-
Grasso, Maurizia, Arbustini, Eloisa, Silini, Enrico, Diegoli, Marta, Percivalle, Elena, Ratti, Giulio, Bramerio, Manuela, Gavazzi, Antonello, Vigano, Mario, and Milanesi, Gabriele
- Subjects
Coxsackieviruses -- Diagnosis ,Cardiomyopathy, Dilated -- Diagnosis ,Gene amplification -- Usage ,Health - Abstract
A polymerase chain reaction (PCR) amplification assay was developed to detect Coxsackievirus B3 ribonucleic acid (RNA) in blood and myocardial tissue of explanted hearts from 40 patients who underwent cardiac transplantation and in 1 normal heart. Twenty-one patients were affected duration dilated cardiomyopathy of different duration and 19 by coronary artery disease. Coxsackievirus B3 in vitro infected Vero cells and cells infected by related human enteroviruses (Coxsackievirus B2, B4, and poliovirus 1) were used as reaction controls. PCR was performed using 4 pairs of primers homologous to Coxsackievirus B3 sequences. Three sets were located in regions of the genome conserved at nucleotide level between several entervirus species (replicase gene, 5' noncoding region), while one was located in a Coxsackievirus B3-specific region (VP1 gene). Total RNA was prepared by acid guanidinium isothyocyanate extraction from tissue stored frozen at -80 [degrees] C. One microgram of total RNA was retrotranscribed with either antisense primer or with random hexanucleotide primers and then subjected to 40 cycles of amplification. PCR products were separated byd electrophoresis on a 10% polyacrilamide gel, electrotransferred to a nylon membrane and then hybridized to oligonucleotide probes specific for the coxsackievirus B3 genome radiolabeled with radioactive isotope of phosphorous. All pairs of primers yielded specific amplification products when tested on Coxsackievirus B3-infected Vero cells, with a sensitivity of 1 infected cell out of [10.sup.5] to [10.sup.6] cells starting from 1 [mu]g total RNA. Primer sets for regions of Coxsackievirus B3 genome highly conserved between related enteroviral species gave positive amplification also when challenged with RNA from cells infected by Coxsackievirus B2, B4 and poliovirus 1. The VP1 gene primer set produced positive amplification only with RNA of Coxsackievirus B3-infected cells. Coxsackievirus B3-specific amplification products were distinguished from those of related enteroviruses by hybridization with specific oligoprobes. However, Coxsackievirus B2, B4 and poliovirus 1-specific PCR products showed positive hybridization if probed with Coxsackievirus B3 genomic probes. All total RNAs from blood and myocardial samples examined by our PCR assay failed to reveal any amplification product that could be related to Coxsackievirus B3 or to enteroviruses in general, after gel electrophoresis and low stringency Southern blot hybridization with the Coxsackievirus B3 specific oligoprobes or the Coxsackievirus B3 genomic probes. The negative results obtained in our series question the hypothesized widespread persistence of enteroviral RNA in hearts with idiopathic dilated cardiomyopathy.
- Published
- 1992
243. H and L ferritins in myocardium in iron overload
- Author
-
Arbustini, Eloisa, Grasso, Maurizia, Rindi, Guido, Arosio, Paolo, Gavazzi, Antonello, Diegoli, Marta, Bramerio, Manuela, Levi, Sonia, and Barosi, Giovanni
- Subjects
Ferritin -- Physiological aspects ,Iron in the body -- Physiological aspects ,Heart muscle -- Physiological aspects ,Health - Published
- 1991
244. Coronary atherosclerotic plaques with and without thrombus in ischemic heart syndromes: a morphologic, immunohistochemical, and biochemical study
- Author
-
Arbustini, Eloisa, Grasso, Maurizia, Diegoli, Marta, Pucci, Angela, Bramerio, Manuela, Ardissino, Diego, Angoli, Luigi, de Servi, Stefano, Bramucci, Ezio, Mussini, Antonio, Minzioni, Gaetano, Vigano, Mario, and Specchia, Giuseppe
- Subjects
Thrombosis -- Development and progression ,Coronary heart disease -- Physiological aspects ,Atherosclerotic plaque -- Development and progression ,Health - Abstract
Ischemic syndromes are a collection of disorders in which the heart muscle does not receive an adequate supply of blood. Atherosclerosis, in which the arteries of the heart are partially blocked by fat-laden lesions, is very common in ischemic heart disease, but it is also common among people without ischemic heart disease. Ischemic heart disease may be stable or unstable. An example of a stable ischemic condition is stable angina, in which drugs designed to relax the blood vessels and improve blood flow often control the problem. Unstable ischemic syndromes include unstable angina and myocardial infarction (heart attack). These unstable conditions appear to be associated with the formation of blood clots, or thrombi, within the arteries of the heart. The formation of these blood clots seems to begin in an atherosclerotic lesion. Since atherosclerosis is so common, it is important to determine why some atherosclerotic conditions are stable and lead to only relatively benign disease while others are unstable and are more likely to result in heart attack or sudden death. To evaluate the distinctions among different patients with atherosclerosis, samples of artery tissue were examined from patients with stable, unstable, and nonischemic disease. These specimens were obtained during autopsy or surgery. It was found that extensive narrowing (stenosis) of the coronary arteries was common; it was present in 90 percent of cases of stable and unstable disease. Furthermore, stenosis was found in about half the patients with nonischemic disease. Researchers observed, however, that the composition of the plaque seemed to influence the likelihood of clot formation within the artery. Thrombi were more likely to be associated with atherosclerotic lesions that were mostly fatty pulp, that is, pultaceous. In contrast, thrombi were less likely to be associated with atherosclerotic lesions that were mostly fibrous. Since a primary step in the development of a thrombus is the adherence of platelets (cells involved in clotting) to the surface of the atherosclerotic lesion, it would seem that the characteristics of this surface play a major role in the progression of thrombosis. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1991
245. Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry
- Author
-
Gimeno, Juan R, Elliott, Perry M, Tavazzi, Luigi, Tendera, Michal, Kaski, Juan P, Laroche, Cecile, Barriales-Villa, Roberto, Seferovic, Petar, Biagini, Elena, Arbustini, Eloisa, Lopes, Luis R, Linhart, Ales, Mogensen, Jens, Hagege, Albert, Espinosa, Maria A, Saad, Aly, Maggioni, Aldo P, Caforio, Alida L P, and Charron, Philippe H
- Abstract
Graphical Abstract
- Published
- 2021
- Full Text
- View/download PDF
246. Expression of natriuretic peptide in ventricular myocardium of failing human hearts and its correlation with the severity of clinical and hemodynamic impairment
- Author
-
Arbustini, Eloisa, Pucci, Angela, Grasso, Maurizia, Diegoli, Marta, Pozzi, Roberto, Gavazzi, Antonello, Graziano, Gabriella, Campana, Carlo, Goggi, Claudio, Martinelli, Luigi, Silini, Enrico, Specchia, Guiseppe, Vigano, Mario, and Solcia, Enrico
- Subjects
Heart failure -- Complications ,Heart failure -- Physiological aspects ,Heart ventricle, Left -- Physiological aspects ,Natriuretic peptides -- Physiological aspects ,Health - Abstract
Atrial natriuretic peptide (ANP) is a substance secreted by the atrium of the heart in response to stretching of cardiac tissue (such as occurs during hypertensive episodes or congestive heart failure). It causes excretion of sodium in the urine, dilation of the blood vessels, and other physiological responses that tend to reduce the workload of the heart. Human atrial myocytes (muscle cells) have been shown to contain ANP. In heart failure, ventricular myocytes also appear to contain and secrete ANP. This results from an induction (turning on) of the normally inactive ventricular ANP gene. To investigate the factors involved in the re-expression of the ANP gene in failing human hearts, a microscopic study was undertaken to analyze muscle tissue from 87 healthy hearts, one heart from a patient with hepatitis B, 151 hearts from patients with dilated cardiomyopathy (a type of heart disease), 26 explanted hearts with dilated cardiomyopathy, and 31 explanted hearts with ischemic heart disease (cardiac damage resulting from decreased blood flow). Hearts were treated with specific stains to detect the presence of ANP. The ventricles of normal hearts were completely devoid of ANP. Ventricular ANP was found in 30 to 60 percent of the ventricles of the failing hearts, and the presence and extent of ventricular ANP was not related to the type of heart disease. However, there was a correlation between the amount of ventricular ANP and both the severity of the disease symptoms and several physiological indices of cardiovascular dysfunction. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
247. A Multidimensional Approach of Surgical Mortality Assessment and Stratification (Smatt Score).
- Author
-
Cutti, Sara, Klersy, Catherine, Favalli, Valentina, Cobianchi, Lorenzo, Muzzi, Alba, Rettani, Marco, Tavazzi, Guido, Delmonte, Maria Paola, Peloso, Andrea, Arbustini, Eloisa, and Marena, Carlo
- Subjects
SURGICAL emergencies ,HOSPITAL mortality ,MEDICAL centers ,HOSPITAL care ,BODY mass index - Abstract
Surgical mortality is the most significant measure of outcome in surgical healthcare. The objective was to assess surgical 30 days mortality and improve the identification of predictors for personalized risk stratification of patients undergoing elective and emergency surgery. The study was conducted as a single-center cohort retrospective observational study, based on the analysis of data collected from patients surgically treated from 2002 to 2014 in a multi-disciplinary research and care referral hospital with global case mix of 1.27. The overall in-hospital mortality rate was 1.89% (95% CI 1.82–1.95). In the univariable analysis, numerous predictors were significantly associated with in-hospital death following surgery. In the multivariable model, age, BMI (Body Mass Index), ASA score, department, planned surgical complexity, surgical priority, previous surgeries in the same hospitalization, cardiovascular, pulmonary, hepato-renal comorbidities, drug intolerance, cancer and AIDS were independently associated with mortality after surgery. At logistic regression, the computed SMATT score (graded 0–100), generated on the basis of multivariate analysis, demonstrated a good discrimination (10-fold cross-validated AUC-ROC 0.945, 95%CI 0.941–0.948) and correctly classified 98.5% of those admissions with a probability of death >50%. The novel SMATT score, based on individual preoperative and surgical factors, accurately predicts mortality and provides dynamic information of the risk in redo/reoperative surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
248. Pathologic substrate of gastropathy in Anderson-Fabry disease.
- Author
-
Di Toro, Alessandro, Narula, Nupoor, Giuliani, Lorenzo, Concardi, Monica, Smirnova, Alexandra, Favalli, Valentina, Urtis, Mario, Alvisi, Costanza, Antoniazzi, Elena, and Arbustini, Eloisa
- Subjects
ANGIOKERATOMA corporis diffusum ,NEURONS ,ENDOENZYMES ,GENETIC mutation ,GASTROINTESTINAL system ,DIGESTIVE system endoscopic surgery - Abstract
In both classic and late-onset AFD, mutations of the GLA gene cause deficient activity of the alpha-galactosidase enzyme resulting in intracellular accumulation of the undigested substrate. Gastrointestinal symptoms (GI) are common but non-specific and imputed to the AFD, irrespective of the demonstration of substrate accumulation in GI cells. We demonstrate substrate accumulation in gastric epithelial, vascular, and nerve cells of patients with classic AFD and, vice versa, absence of accumulation in late-onset AFD and controls. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
249. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
- Author
-
Bégué, Céline, Mörner, Stellan, Brito, Dulce, Hengstenberg, Christian, Cleland, John G. F., Arbustini, Eloisa, Galve, Enrique, Wichter, Thomas, Richter, Anette, Golmard, Jean-Louis, Bernard, Maguy, Dubourg, Olivier, Komajda, Michel, Charron, Philippe, and Isnard, Richard
- Subjects
BRAIN natriuretic factor ,HYPERTROPHIC cardiomyopathy ,HEART assist devices ,RECEIVER operating characteristic curves ,MULTIPLE regression analysis ,VENTRICULAR ejection fraction ,HEART failure - Abstract
Objectives: N-terminal probrain natriuretic peptide (NT-proBNP) predicts mortality and the development of heart failure in hypertrophic cardiomyopathy (HCM). Mid-regional proatrial natriuretic peptide (MR-proANP) is a stable by-product of production of atrial natriuretic peptide. We sought to compare the prognostic value of MR-proANP and NT-proBNP in HCM.Methods: We prospectively enrolled a cohort of patients with HCM from different European centres and followed them. All patients had clinical, ECG and echocardiographic evaluation and measurement of MR-proANP and NT-proBNP at inclusion.Results: Of 357 patients enrolled, the median age was 52 (IQR: 36-65) years. MR-proANP and NT-proBNP were both independently associated with age, weight, New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), wall thickness and left atrial dimension. During a median follow-up of 23 months, 32 patients had a primary end point defined as death (n=6), heart transplantation (n=8), left ventricular assist device implantation (n=1) or heart failure hospitalisation (n=17). Both NT-proBNP and MR-proANP (p<10-4) were strongly associated with the primary endpoint, and the areas under the receiver operating characteristic (ROC) curves for both peptides were not significantly different. However, in a multiple stepwise regression analysis, the best model for predicting outcome was NYHA 1-2 vs 3-4 (HR=0.35, 95% CI 0.16 to 0.77, p<0.01), LVEF (HR=0.96, 95% CI 0.94 to 0.98, p=0.0005) and MR-proANP (HR=3.77, 95% CI 2.01 to 7.08, p<0.0001).Conclusions: MR-proANP emerges as a valuable biomarker for the prediction of death and heart failure related events in patients with HCM. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
250. Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center.
- Author
-
Garcia-Etienne, Carlos A., Ferrari, Alberta, Della Valle, Angelica, Lucioni, Marco, Ferraris, Elisa, Di Giulio, Giuseppe, Squillace, Luigi, Bonzano, Elisabetta, Lasagna, Angioletta, Rizzo, Gianpiero, Tancredi, Richard, Scotti Foglieni, Andrea, Dionigi, Francesca, Grasso, Maurizia, Arbustini, Eloisa, Cavenaghi, Giorgio, Pedrazzoli, Paolo, Filippi, Andrea R., Dionigi, Paolo, and Sgarella, Adele
- Subjects
SENTINEL lymph node biopsy ,AXILLARY lymph node dissection ,HORMONE receptor positive breast cancer ,BREAST cancer ,AXILLA ,SENTINEL lymph nodes ,BREAST ,HORMONE receptors - Abstract
The surgical approach to the axilla in breast cancer has been a controversial issue for more than three decades. Data from recently published trials have provided practice-changing recommendations in this scenario. However, further controversies have been triggered in the surgical community, resulting in heterogeneous diffusion of these recommendations. The development of clinical guidelines for the management of the axilla in patients with breast cancer is a work in progress. A multidisciplinary team discussion was held at the research hospital Policlinico San Matteo from the Università degli Studi di Pavia with the aim to update recommendations for the management of the axilla in patients with breast cancer. An evidence-based approach is presented. Our multidisciplinary panel determined that axillary dissection after a positive sentinel lymph node biopsy may be avoided in cN0 patients with micro/macrometastasis to ≤2 sentinel nodes, with age ≥40y, lesions ≤3 cm, who have not received neoadjuvant chemotherapy and have planned breast conservation (BCS) with whole breast radiotherapy (WBRT). Cases with gross (>2 mm) ECE in SLNs are evaluated on individual basis for completion ALND, axillary radiotherapy or omission of both. Patients fulfilling the criteria listed above who undergo mastectomy, may also avoid axillary dissection after multidisciplinary discussion of individual cases for consideration of axillary irradiation. Women 70 years or older with hormone receptors positive invasive lesions ≤3 cm, clinically negative nodes, and serious or multiple comorbidities who undergo BCS with WBRT, may forgo axillary staging/surgery (if mastectomy or larger tumor, comorbidities and life expectancy are taken into account). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.